Catheter ablation may significantly improve cardiac and renal function among AF patients with mid-range ejection fraction
Catheter ablation as an effective treatment for atrial fibrillation (AF), and it is currently the first-line treatment for AF. The efficacy of catheter ablation in patients with low cardiac function has been previously reported; however, only a few studies have included mid-range ejection fraction (mrEF).
A study published in Indian Pacing and Electrophysiology Journal On 27 June 2023, entitled “Efficacy and safety of atrial fibrillation ablation in heart failure patients with left ventricular ejection fraction less than 50%” by Sakamoto et al. and colleagues highlighted the effectiveness and safety of ablation in patients with a history of reduced left ventricular function including mid-range ejection fraction.
The present study included 79 patients with a left ventricular ejection fraction of less than 50%. These patients underwent catheter ablation for atrial fibrillation.
Mentioning the study background, they said previous data and research have already emphasized catheter ablation efficacy in those with low cardiac function. There needs to be more research and data on mid-range ejection fraction (MRF).
The main aim of this study was the evaluation of the efficacy and safety of atrial fibrillation (AF) ablation those having left ventricular ejection fraction (LVEF) < 50%.
The key highlights of this study are:
- Postoperative sick sinus syndrome and inguinal hematoma were reported in one patient as complications.
- Emphasizing efficacy, improvements were noted in echocardiographic data, blood test values, and diuretic use.
- Following 60 months of follow-up, 86.1% of patients reported no AF recurrence.
- There were nine heart failure hospitalizations 11.4%) and five all-cause deaths constituting 11.4 % and 6.3%, respectively.
- There were no significant differences between the rEF and more groups.
- Researchers reported no significant predictors of AF recurrence in preoperative patient characteristics.
They said Atrial fibrillation ablation is tied to improved cardiac and renal function in patients with LVEF <50%. It also has fewer complications, they noted.
The study's limitations include small sample size, lack of follow-ups and long-term monitoring.
Further reading:
https://www.sciencedirect.com/science/article/pii/S0972629223000748
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd